KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Non-cash Items (2019 - 2022)

Historic Non-cash Items for Vir Biotechnology (VIR) over the last 4 years, with Q4 2022 value amounting to $127.4 million.

  • Vir Biotechnology's Non-cash Items fell 2777.78% to $127.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was $127.4 million, marking a year-over-year decrease of 2777.78%. This contributed to the annual value of $127.4 million for FY2022, which is 2777.78% down from last year.
  • According to the latest figures from Q4 2022, Vir Biotechnology's Non-cash Items is $127.4 million, which was down 2777.78% from $192.2 million recorded in Q1 2022.
  • In the past 5 years, Vir Biotechnology's Non-cash Items registered a high of $290.1 million during Q1 2021, and its lowest value of $55.1 million during Q4 2019.
  • In the last 4 years, Vir Biotechnology's Non-cash Items had a median value of $182.9 million in 2021 and averaged $175.7 million.
  • As far as peak fluctuations go, Vir Biotechnology's Non-cash Items soared by 11338.42% in 2020, and later plummeted by 3374.33% in 2022.
  • Over the past 4 years, Vir Biotechnology's Non-cash Items (Quarter) stood at $55.1 million in 2019, then soared by 113.38% to $117.5 million in 2020, then skyrocketed by 50.13% to $176.4 million in 2021, then dropped by 27.78% to $127.4 million in 2022.
  • Its Non-cash Items was $127.4 million in Q4 2022, compared to $192.2 million in Q1 2022 and $176.4 million in Q4 2021.